Redeye: IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials
Redeye provides a research update following IRLAB's Q2 report. We note that capital allocation and operational efficiency following the recent rights issue will be important to realize the company's pipeline value.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/